Drug intelligence / Profile preview

ANN-102

Development stage: Preclinical
Lead developer: Anodyne Nanotech
Modality: Small Molecules

Overview

ANN-102 is a first-in-class APJ receptor agonist being developed for the treatment of sarcopenia. The drug is designed to target the APJ receptor, which plays a role in muscle physiology and may help address muscle wasting conditions such as sarcopenia. It is under development by Anodyne Nanotech[1].

Targets

APLNR (Apelin receptor)

Beyond the preview

Go deeper on ANN-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANN-102.

Explore the full profile